Shariaportfolio Inc. Increases Holdings in Becton, Dickinson and Company $BDX

Key Points

• Shariaportfolio Inc. increased its stake in Becton, Dickinson and Company by 23.4%, holding a total of 9,804 shares worth approximately $1.69 million.
• Several institutional investors, including the Saudi Central Bank and Smallwood Wealth Investment Management, have recently acquired new stakes in Becton, Dickinson, indicating a growing interest, as institutional ownership now stands at 86.97%.
• Becton, Dickinson and Company reported earnings of $3.68 per share for the last quarter, surpassing consensus estimates and reflecting a year-over-year revenue increase of 10.4%.

Shariaportfolio Inc. lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 23.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,804 shares of the medical instruments supplier's stock after acquiring an additional 1,861 shares during the quarter. Becton, Dickinson and Company accounts for about 0.7% of Shariaportfolio Inc.'s holdings, making the stock its 17th biggest position. Shariaportfolio Inc.'s holdings in Becton, Dickinson and Company were worth $1,689,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BDX. Saudi Central Bank purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $26,000. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $27,000. Alpine Bank Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC boosted its stake in shares of Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $31,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock worth $562,036 over the last ninety days. Corporate insiders own 0.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Royal Bank Of Canada assumed coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a "sector perform" rating and a $211.00 target price on the stock. Morgan Stanley upped their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research note on Saturday, September 27th. Argus upped their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $205.40.

Becton, Dickinson and Company Trading Up 0.3%

Shares of BDX opened at $192.56 on Wednesday. The stock has a fifty day moving average of $189.41 and a two-hundred day moving average of $186.83. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a market capitalization of $55.19 billion, a PE ratio of 34.63, a price-to-earnings-growth ratio of 1.50 and a beta of 0.25. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.Becton, Dickinson and Company's revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.